Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation.
暂无分享,去创建一个
M Ingelman-Sundberg | M. Ingelman-Sundberg | L. Bertilsson | G. Alván | M. Dahl | F. Sjöqvist | M L Dahl | F Sjöqvist | L Bertilsson | G Alvan | G. Alvan
[1] G. Aithal,et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.
[2] L. Bertilsson,et al. Polymorphic Drug Oxidation , 1996 .
[3] M. Ingelman-Sundberg,et al. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population , 1992, Clinical pharmacology and therapeutics.
[4] M. Ingelman-Sundberg,et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[5] Proceedings: N-oxidation of sparteine in man and its interindividual differences. , 1975, Naunyn-Schmiedeberg's archives of pharmacology.
[6] U. Meyer,et al. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.
[7] M. Dahl,et al. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. , 2000, Therapeutic drug monitoring.
[8] V. McKusick,et al. Genetic Control of Isoniazid Metabolism in Man , 1960, British medical journal.
[9] L. Bertilsson,et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine , 1998, Clinical pharmacology and therapeutics.
[10] L. Bertilsson,et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.
[11] L. Bertilsson,et al. Clinical pharmacology of antidepressant drugs: pharmacogenetics. , 1984, Advances in biochemical psychopharmacology.
[12] M. Ingelman-Sundberg,et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.
[13] L. Bertilsson,et al. 10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes , 1998, Clinical pharmacology and therapeutics.
[14] C. Halldin,et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. , 1995, The American journal of psychiatry.
[15] L. Bertilsson,et al. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. , 1999, British journal of clinical pharmacology.
[16] M. Ingelman-Sundberg,et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. , 1995, The Journal of pharmacology and experimental therapeutics.
[17] J. Idle,et al. POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.
[18] M. Ingelman-Sundberg,et al. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.
[19] C. Alm,et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. , 1992, Therapeutic drug monitoring.
[20] M. Eichelbaum,et al. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. , 1991, DNA and cell biology.
[21] J. Lindsten,et al. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin , 1985, Clinical pharmacology and therapeutics.
[22] L. Bertilsson,et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. , 1995, British journal of clinical pharmacology.
[23] A. Marshall. Laying the foundations for personalized medicines , 1998, Nature Biotechnology.